ロード中...
JAK2 inhibitors for myeloproliferative neoplasms: what is next?
Since its approval in 2011, the Janus kinase 1/2 (JAK1/2) inhibitor ruxolitinib has evolved to become the centerpiece of therapy for myelofibrosis (MF), and its use in patients with hydroxyurea resistant or intolerant polycythemia vera (PV) is steadily increasing. Several other JAK2 inhibitors have...
保存先:
| 出版年: | Blood |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Society of Hematology
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510786/ https://ncbi.nlm.nih.gov/pubmed/28500170 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-04-742288 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|